Cargando…

Mucosal‐associated invariant T‐cell frequency and function in blood and liver of HCV mono‐ and HCV/HIV co‐infected patients with advanced fibrosis

BACKGROUND & AIMS: Mucosal‐associated invariant T (MAIT) cells are important innate T cells with antimicrobial and immunoregulatory activity, recently found to be depleted in blood of patients with HIV and HCV mono‐infections. In this study, we assessed the impact of HIV, HCV and HCV/HIV co‐infe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beudeker, Boris J. B., van Oord, Gertine W., Arends, Joop E., Schulze zur Wiesch, Julian, van der Heide, Marieke S., de Knegt, Robert J., Verbon, Annelies, Boonstra, Andre, Claassen, Mark A. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Viral Hepatitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836956/ https://www.ncbi.nlm.nih.gov/pubmed/28792648 http://dx.doi.org/10.1111/liv.13544

Ejemplares similares

Histological changes in HCV antibody–positive, HCV RNA–negative subjects suggest persistent virus infection
por: Hoare, Matthew, et al.
Publicado: (2008)

Treatment induced clearance of hepatitis E viruses by interferon‐lambda in liver‐humanized mice
por: Sari, Gulce, et al.
Publicado: (2021)

HCV disease burden and population segments in Switzerland
por: Bihl, Florian, et al.
Publicado: (2021)

Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population
por: Schmidbauer, Caroline, et al.
Publicado: (2020)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

SNP rs688 within the low‐density lipoprotein receptor (LDL‐R) gene associates with HCV susceptibility
por: Steba, Gaby S., et al.
Publicado: (2018)

Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens
por: Reddy, K. Rajender, et al.
Publicado: (2017)

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
por: Brown, Ashley, et al.
Publicado: (2019)

Peripheral neuropathy after viral eradication with direct‐acting antivirals in chronic HCV hepatitis: A prospective study
por: Zanone, Maria M., et al.
Publicado: (2021)

Feasibility and effectiveness of HCV viraemia testing at harm reduction sites in Georgia: A prospective three‐arm study
por: Shilton, Sonjelle, et al.
Publicado: (2022)

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies
por: Yao, Betty B., et al.
Publicado: (2020)

Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy
por: Spaan, Michelle, et al.
Publicado: (2016)

Identification of novel neutralizing determinants for protection against HCV
por: Alzua, Garazi P., et al.
Publicado: (2023)

Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity in the blood and liver in chronic hepatitis B patients
por: Genshaft, Alex S., et al.
Publicado: (2023)

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus
por: van de Ven, Nikolien, et al.
Publicado: (2015)

Flunarizine prevents hepatitis C virus membrane fusion in a genotype‐dependent manner by targeting the potential fusion peptide within E1
por: Perin, Paula M., et al.
Publicado: (2015)

Maternal and fetal outcomes of pregnancies complicated by acute hepatitis E and the impact of HIV status: A cross‐sectional study in Namibia
por: Heemelaar, Steffie, et al.
Publicado: (2021)

Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non‐responders: Double‐blinded, randomised, controlled phase 2 trial
por: Koc, Özgür M., et al.
Publicado: (2021)

microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C
por: Van Keuren‐Jensen, Kendall R., et al.
Publicado: (2015)

Estimating the Net Contribution of Interleukin-28B Variation to Spontaneous Hepatitis C Virus Clearance
por: di Iulio, Julia, et al.
Publicado: (2011)

Expression of Paramyxovirus V Proteins Promotes Replication and Spread of Hepatitis C Virus in Cultures of Primary Human Fetal Liver Cells
por: Andrus, Linda, et al.
Publicado: (2011)

Effect of Immune Pressure on Hepatitis C Virus Evolution: Insights From a Single-Source Outbreak
por: Merani, Shahzma, et al.
Publicado: (2011)

Transcriptome Sequencing, Microarray, and Proteomic Analyses Reveal Cellular and Metabolic Impact of Hepatitis C Virus Infection In Vitro
por: Woodhouse, Stephen D, et al.
Publicado: (2010)

IFITM1 is a tight junction protein that inhibits hepatitis C virus entry,
por: Wilkins, Courtney, et al.
Publicado: (2013)

Liver-primed CD8(+) T cells suppress antiviral adaptive immunity through galectin-9-independent T-Cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice
por: Dolina, Joseph S, et al.
Publicado: (2014)

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
por: Gordon, Stuart C, et al.
Publicado: (2013)

Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals
por: Martin, Natasha K, et al.
Publicado: (2013)

Paracrine Signals From Liver Sinusoidal Endothelium Regulate Hepatitis C Virus Replication
por: Rowe, Ian A, et al.
Publicado: (2014)

Branched-chain amino acids reduce hepatic iron accumulation and oxidative stress in hepatitis C virus polyprotein-expressing mice
por: Korenaga, Masaaki, et al.
Publicado: (2015)

DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection
por: Burza, Maria Antonella, et al.
Publicado: (2015)

Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data
por: Wilder, Julius M., et al.
Publicado: (2015)

Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine‐induced neutralizing activity
por: Kachko, Alla, et al.
Publicado: (2015)

Structure-Guided Design Affirms Inhibitors of Hepatitis C Virus p7 as a Viable Class of Antivirals Targeting Virion Release
por: Foster, Toshana L, et al.
Publicado: (2014)

Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C
por: Tsochatzis, Emmanuel A, et al.
Publicado: (2014)

Type I interferon rapidly restricts infectious hepatitis C virus particle genesis
por: Meredith, Luke W, et al.
Publicado: (2014)

Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)
por: Watashi, Koichi, et al.
Publicado: (2014)

Chronic hepatitis C viral infection subverts vaccine‐induced T‐cell immunity in humans
por: Kelly, Christabel, et al.
Publicado: (2016)

Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt
por: Benova, Lenka, et al.
Publicado: (2015)

Hepatitis E virus and fulminant hepatitis–a virus or host-specific pathology?
por: Smith, Donald B, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iteg8bcqu0vpklnaqrjeoro856